{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:08:37Z","timestamp":1770919717142,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Acadia Pharmaceuticals Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40261-022-01156-4","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T11:03:48Z","timestamp":1653649428000},"page":"513-524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects"],"prefix":"10.1007","volume":"42","author":[{"given":"Mona","family":"Darwish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Harlick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryl","family":"DeKarske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Stankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"1156_CR1","doi-asserted-by":"publisher","first-page":"e1912","DOI":"10.1212\/wnl.0000000000007316","volume":"92","author":"DG Glaze","year":"2019","unstructured":"Glaze DG, Neul JL, Kaufmann WE, Berry-Kravis E, Condon S, Stoms G, Oosterholt S, Della Pasqua O, Glass L, Jones NE, Percy AK, Rett 002 Study Group. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019;92:e1912\u201325. https:\/\/doi.org\/10.1212\/wnl.0000000000007316.","journal-title":"Neurology"},{"key":"1156_CR2","doi-asserted-by":"publisher","first-page":"170216","DOI":"10.1098\/rsob.170216","volume":"8","author":"SM Kyle","year":"2018","unstructured":"Kyle SM, Vashi N, Justice MJ. Rett syndrome: a neurological disorder with metabolic components. Open Biol. 2018;8:170216. https:\/\/doi.org\/10.1098\/rsob.170216.","journal-title":"Open Biol"},{"key":"1156_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/mp.2018.5","volume":"23","author":"N Mellios","year":"2018","unstructured":"Mellios N, Feldman DA, Sheridan SD, Ip JPK, Kwok S, Amoah SK, Rosen B, Rodriguez BA, Crawford B, Swaminathan R, Chou S, Li Y, Ziats M, Ernst C, Jaenisch R, Haggarty SJ, Sur M. Human cerebral organoids reveal deficits in neurogenesis and neuronal migration in MeCP2-deficient neural progenitors. Mol Psychiatry. 2018;23:791. https:\/\/doi.org\/10.1038\/mp.2018.5.","journal-title":"Mol Psychiatry"},{"key":"1156_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090645","volume":"9","author":"CO Olson","year":"2014","unstructured":"Olson CO, Zachariah RM, Ezeonwuka CD, Liyanage VR, Rastegar M. Brain region-specific expression of MeCP2 isoforms correlates with DNA methylation within Mecp2 regulatory elements. PLoS One. 2014;9:e90645. https:\/\/doi.org\/10.1371\/journal.pone.0090645.","journal-title":"PLoS One"},{"key":"1156_CR5","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1086\/345360","volume":"71","author":"MD Shahbazian","year":"2002","unstructured":"Shahbazian MD, Zoghbi HY. Rett syndrome and MeCP2: linking epigenetics and neuronal function. Am J Hum Genet. 2002;71:1259\u201372. https:\/\/doi.org\/10.1086\/345360.","journal-title":"Am J Hum Genet"},{"key":"1156_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1203\/PDR.0b013e3182242461","volume":"70","author":"S Fehr","year":"2011","unstructured":"Fehr S, Bebbington A, Nassar N, Downs J, Ronen GM, De Klerk N, Leonard H. Trends in the diagnosis of Rett syndrome in Australia. Pediatr Res. 2011;70:313\u20139. https:\/\/doi.org\/10.1203\/PDR.0b013e3182242461.","journal-title":"Pediatr Res"},{"key":"1156_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1651-2227.1985.tb10993.x","volume":"74","author":"B Hagberg","year":"1985","unstructured":"Hagberg B. Rett\u2019s syndrome: prevalence and impact on progressive severe mental retardation in girls. Acta Paediatr Scand. 1985;74:405\u20138. https:\/\/doi.org\/10.1111\/j.1651-2227.1985.tb10993.x.","journal-title":"Acta Paediatr Scand"},{"issue":"Suppl 1","key":"1156_CR8","first-page":"8","volume":"6","author":"H Leonard","year":"1997","unstructured":"Leonard H, Bower C, English D. The prevalence and incidence of Rett syndrome in Australia. Eur Child Adolesc Psychiatry. 1997;6(Suppl 1):8\u201310.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"1156_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jpeds.2009.07.015","volume":"156","author":"RS Kirby","year":"2010","unstructured":"Kirby RS, Lane JB, Childers J, Skinner SA, Annese F, Barrish JO, Glaze DG, MacLeod P, Percy AK. Longevity in Rett syndrome: analysis of the North American Database. J Pediatr. 2010;156:135\u20138.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2009.07.015.","journal-title":"J Pediatr"},{"key":"1156_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.pediatrneurol.2015.06.003","volume":"53","author":"DC Tarquinio","year":"2015","unstructured":"Tarquinio DC, Hou W, Neul JL, Kaufmann WE, Glaze DG, Motil KJ, Skinner SA, Lee HS, Percy AK. The changing face of survival in Rett syndrome and MECP2-related disorders. Pediatr Neurol. 2015;53:402\u201311. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2015.06.003.","journal-title":"Pediatr Neurol"},{"key":"1156_CR11","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s10803-017-3034-3","volume":"47","author":"JB Lane","year":"2017","unstructured":"Lane JB, Salter AR, Jones NE, Cutter G, Horrigan J, Skinner SA, Kaufmann WE, Glaze DG, Neul JL, Percy AK. Assessment of caregiver inventory for Rett syndrome. J Autism Dev Disord. 2017;47:1102\u201312. https:\/\/doi.org\/10.1007\/s10803-017-3034-3.","journal-title":"J Autism Dev Disord"},{"key":"1156_CR12","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1073\/pnas.0812394106","volume":"106","author":"D Tropea","year":"2009","unstructured":"Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, Flannery R, Jaenisch R, Sur M. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA. 2009;106:2029\u201334. https:\/\/doi.org\/10.1073\/pnas.0812394106.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1156_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jns.2008.12.003","volume":"278","author":"MJ Bickerdike","year":"2009","unstructured":"Bickerdike MJ, Thomas GB, Batchelor DC, Sirimanne ES, Leong W, Lin H, Sieg F, Wen J, Brimble MA, Harris PW, Gluckman PD. NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke. J Neurol Sci. 2009;278:85\u201390. https:\/\/doi.org\/10.1016\/j.jns.2008.12.003.","journal-title":"J Neurol Sci"},{"issue":"Suppl","key":"1156_CR14","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/j.ejps.2017.05.032","volume":"109","author":"SP Oosterholt","year":"2017","unstructured":"Oosterholt SP, Horrigan J, Jones N, Glass L, Della PO. Population pharmacokinetics of NNZ-2566 in healthy subjects. Eur J Pharm Sci. 2017;109(Suppl):S98\u2013107. https:\/\/doi.org\/10.1016\/j.ejps.2017.05.032.","journal-title":"Eur J Pharm Sci"},{"key":"1156_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/bf01061694","volume":"5","author":"PG Welling","year":"1977","unstructured":"Welling PG. Influence of food and diet on gastrointestinal drug absorption: a review. J Pharmacokinet Biopharm. 1977;5:291\u2013334. https:\/\/doi.org\/10.1007\/bf01061694.","journal-title":"J Pharmacokinet Biopharm"},{"key":"1156_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0163-7258(89)90019-3","volume":"43","author":"PG Welling","year":"1989","unstructured":"Welling PG. Effects of food on drug absorption. Pharmacol Ther. 1989;43:425\u201341. https:\/\/doi.org\/10.1016\/0163-7258(89)90019-3.","journal-title":"Pharmacol Ther"},{"key":"1156_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1517\/17425255.4.2.175","volume":"4","author":"M Baraldo","year":"2008","unstructured":"Baraldo M. The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol. 2008;4:175\u201392. https:\/\/doi.org\/10.1517\/17425255.4.2.175.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1156_CR18","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: food-effect bioavailability and fed bioequivalence studies. December 2002. https:\/\/www.fda.gov\/media\/70945\/download. Accessed Oct 2021."},{"key":"1156_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2165\/00003088-199937030-00003","volume":"37","author":"B Singh","year":"1999","unstructured":"Singh B. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet. 1999;37:213\u201355. https:\/\/doi.org\/10.2165\/00003088-199937030-00003.","journal-title":"Clin Pharmacokinet"},{"key":"1156_CR20","unstructured":"Oosterholt S, Jones N, Glass L, Della Pasqua O. Population pharmacokinetics of trofinetide in paediatric Rett syndrome patients. In: pA2 online. E-journal of the British Pharmacological Society. 2017. http:\/\/www.pa2online.org\/abstract\/abstract.jsp?abid=33628&author=Oosterholt&cat=-1&period=67. Accessed Oct 2021."},{"key":"1156_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2017.07.002","volume":"76","author":"DG Glaze","year":"2017","unstructured":"Glaze DG, Neul JL, Percy A, Feyma T, Beisang A, Yaroshinsky A, Stoms G, Zuchero D, Horrigan J, Glass L, Jones NE. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome. Pediatr Neurol. 2017;76:37\u201346. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.07.002.","journal-title":"Pediatr Neurol"},{"key":"1156_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pediatrneurol.2020.04.019","volume":"110","author":"E Berry-Kravis","year":"2020","unstructured":"Berry-Kravis E, Horrigan JP, Tartaglia N, Hagerman R, Kolevzon A, Erickson CA, Hatti S, Snape M, Yaroshinsky A, Stoms G, Glass L, Jones NE, FXS-001 Investigators. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of fragile X syndrome. Pediatr Neurol. 2020;110:30\u201341. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2020.04.019.","journal-title":"Pediatr Neurol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01156-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01156-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01156-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T11:20:51Z","timestamp":1654946451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01156-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1156"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01156-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]},"assertion":[{"value":"19 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Acadia Pharmaceuticals Inc. Medical writing and editorial support was provided by Lesley Taylor, PhD, and Stuart Murray, MSc, of Evidence Scientific Solutions, Inc. (Philadelphia, PA) and funded by Acadia Pharmaceuticals Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Acadia Pharmaceuticals Inc. is adhering to current US and EU requirements so will not make individual de-identified participant data available; however, the protocol and statistical analysis plan will be made available upon request to the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All requisite study-related material, including the protocol, were reviewed by an institutional review board\/ethics committee (IntegReview, USA). All subjects provided written informed consent for participation in the study. The study was performed in full conformity with the current Declaration of Helsinki, the International Council for Harmonisation Guideline for Good Clinical Practice, and all other applicable regulations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DD, JH, JMY, MD, and SS are employees of Acadia Pharmaceuticals Inc.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All subjects provided written informed consent for participation in the study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"All authors met ICMJE criteria by contributing to the conception, design, analysis, and\/or interpretation of data; drafting the work or revising it critically for important intellectual content; approving the final version to be published; and agreeing to be accountable for all aspects of the work by ensuring that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}